National Academies Press: OpenBook

Monoclonal Antibody Production (1999)

Chapter: Front Matter

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Monoclonal Antibody Production

Committee on Methods of Producing Monoclonal Antibodies

Institute for Laboratory Animal Research

National Research Council


NATIONAL ACADEMY PRESS
Washington, DC
1999

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

NATIONAL ACADEMY PRESS
2101 Constitution Avenue, N.W. Washington, DC 20418

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This study was supported by Contract No. N0-OD-4-2139 between the National Academy of Sciences and the National Institutes of Health. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

Additional copies of this report are available from:
National Academy Press
2101 Constitution Ave., NW Box 285 Washington, DC 20055 800-624-6242 202-334-3313 (in the Washington metropolitan area) www.nap.edu

Copyright 1999 by the National Academy of Sciences

Printed in the United States of America

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Committee on Methods of Producing Monoclonal Antibodies

PETER A. WARD (Chair),

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan

JANE ADAMS,

Juvenile Diabetes Foundation, Washington, DC

DENISE FAUSTMAN, Immunology Laboratories,

Massachusetts General Hospital, Charlestown, Massachusetts

GERALD F. GEBHART,

Department of Pharmacology, University of Iowa College of Medicine, Iowa City, Iowa

JAMES G. GEISTFELD,

Laboratory Animal Medicine, Taconic Farms, Germantown, New York

JOHN W. IMBARATTO,

Cell Culture Manufacturing, Covance Biotechnology Services, Inc., Research Triangle Park, North Carolina

NORMAN C. PETERSON,

Department of Clinical Studies, University of Pennsylvania, Philadelphia, Pennsylvania

FRED QUIMBY,

Center for Laboratory Animal Resources, Cornell University Veterinary College, Ithaca, New York

ANN MARSHAK-ROTHSTEIN,

Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts

ANDREW N. ROWAN,

Humane Society of the United States, Washington, DC

MATTHEW D. SCHARFF,

Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York

Staff

RALPH B. DELL, Director

KATHLEEN A. BEIL, Administrative Assistant

SUSAN S. VAUPEL, Managing Editor, ILAR Journal

MARSHA K. WILLIAMS, Project Assistant

NORMAN GROSSBLATT, Editor

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Institute for Laboratory Animal Research Council

JOHN VANDEBERG (Chair),

Southwest Foundation for Biomedical Research, San Antonio, Texas

CHRISTIAN R. ABEE,

Department of Comparative Medicine, University of South Alabama, Mobile, Alabama

BENNETT DYKE,

Southwest Foundation for Biomedical Research, San Antonio, Texas

ROSEMARY W. ELLIOTT,

Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, New York

GERALD F. GEBHART,

Department of Pharmacology, College of Medicine, University of Iowa, Iowa City, Iowa

HILTON J. KLEIN,

Department of Laboratory Animal Resources, Merck Research Laboratories, West Point, Pennsylvania

MARGARET LANDI,

Department of Laboratory Animal Science, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

CHARLES R. MCCARTHY,

Kennedy Institute of Ethics, Georgetown University, Washington, DC

HARLEY MOON,

Veterinary Medical Research Institute, Iowa State University, Ames, Iowa

WILLIAM MORTON,

Regional Primate Research Center, University of Washington, Seattle, Washington

ROBERT J. RUSSELL,

Harlan Sprague Dawley, Inc., Indianapolis, Indiana

WILLIAM S. STOKES,

Environmental Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina

JOHN G. VANDENBERGH,

Department of Zoology, North Carolina State University, Raleigh, North Carolina

PETER A. WARD,

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan

THOMAS WOLFLE,

Annapolis, Maryland

JOANNE ZURLO,

Center for Alternatives to Animal Testing, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland

Staff

RALPH B. DELL, Director

KATHLEEN A. BEIL, Administrative Assistant

SUSAN S. VAUPEL, Managing Editor, ILAR Journal

MARSHA K. WILLIAMS, Project Assistant

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Commission on Life Sciences

MICHAEL T. CLEGG (Chair),

College of Natural and Agricultural Sciences, University of California, Riverside, California

PAUL BERG (Vice Chair),

Stanford University School of Medicine, Stanford, California

FREDERICK R. ANDERSON,

Cadwalader, Wickersham & Taft, Washington, DC

JOHN C. BAILAR III,

Department of Health Studies, University of Chicago, Chicago, Illinois

JOANNA BURGER,

Division of Life Sciences, Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey

SHARON L. DUNWOODY,

School of Journalism and Mass Communication, University of Wisconsin, Madison, Wisconsin

DAVID EISENBERG,

University of California, Los Angeles, California

JOHN L. EMMERSON,

Eli Lilly and Co. (ret.), Indianapolis, Indiana

NEAL L. FIRST,

Department of Animal Science, University of Wisconsin, Madison, Wisconsin

DAVID J. GALAS,

Chiroscience R&D, Inc., Bothell, Washington

DAVID V. GOEDDEL,

Tularik, Inc., South San Francisco, California

ARTURO GOMEZ-POMPA,

Department of Botany and Plant Sciences, University of California, Riverside, California

COREY S. GOODMAN,

Department of Molecular and Cell Biology, University of California, Berkeley, California

HENRY W. HEIKKINEN,

Department of Chemistry and Biochemistry, University of Northern Colorado, Greeley, Colorado

BARBARA S. HULKA,

Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina

HANS J. KENDE,

MSU-DOE Plant Research Laboratory, Michigan State University, East Lansing, Michigan

CYNTHIA J. KENYON,

Department of Biochemistry, University of California, San Francisco, California

MARGARET G. KIDWELL,

Department of Ecology and Evolutionary Biology, University of Arizona, Tucson, Arizona

BRUCE R. LEVIN,

Department of Biology, Emory University, Atlanta, Georgia

OLGA F. LINARES,

Smithsonian Tropical Research Institute, Miami, Florida

DAVID M. LIVINGSTON,

Dana-Farber Cancer Institute, Boston, Massachusetts

DONALD R. MATTISON,

March of Dimes, White Plains, New York

ELLIOT M. MEYEROWITZ,

Division of Biology, California Institute of Technology, Pasadena, California

ROBERT T. PAINE,

Department of Zoology, University of Washington, Seattle, Washington

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

RONALD R. SEDEROFF,

Department of Forestry, North Carolina State University, Raleigh, North Carolina

ROBERT R. SOKAL,

Department of Ecology and Evolution, State University of New York at Stony Brook, New York

CHARLES F. STEVENS, MD,

The Salk Institute for Biological Studies, La Jolla, California

SHIRLEY M. TILGHMAN,

Department of Molecular Biology, Princeton University, Princeton, New Jersey

JOHN L. VANDEBERG,

Southwest Foundation for Biomedical Research, San Antonio, Texas

RAYMOND L. WHITE,

Department of Oncological Sciences, University of Utah, Salt Lake City, Utah

Staff

MYRON UMAN,

Acting Executive Director

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Bruce M. Alberts is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. William A. Wulf is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Kenneth I. Shine is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy's purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Bruce M. Alberts and Dr. William A. Wulf are chairman and vice chairman, respectively, of the National Research Council.

Page viii Cite
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
This page in the original is blank.
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Preface

Monoclonal antibodies (mAb) are used extensively in basic biomedical research, in diagnosis of disease, and in treatment of illnesses, such as infections and cancer. Antibodies are important tools used by many investigators in their research and have led to many medical advances.

Producing mAb requires immunizing an animal, usually a mouse; obtaining immune cells from its spleen; and fusing the cells with a cancer cell (such as cells from a myeloma) to make them immortal, which means that they will grow and divide indefinitely. A tumor of the fused cells is called a hybridoma, and these cells secrete mAb. The development of the immortal hybridoma requires the use of animals; no commonly accepted nonanimal alternatives are available.

An investigator who wishes to study a particular protein or other molecule selects a hybridoma cell line that secretes mAb that reacts strongly with that protein or molecule. The cells must grow and multiply to form a clone that will produce the desired mAb. There are two methods for growing these cells: injecting them into the peritoneal cavity of a mouse or using in vitro cell-culture techniques. When injected into a mouse, the hybridoma cells multiply and produce fluid (ascites) in its abdomen; this fluid contains a high concentration of anti-body. The mouse ascites method is inexpensive, easy to use, and familiar.

However, if too much fluid accumulates or if the hybridoma is an aggressive cancer, the mouse will likely experience pain or distress. If a procedure produces pain or distress in animals, regulations call for a search for alternatives. One alternative is to grow hybridoma cells in a tissue-culture medium; this technique requires some expertise, requires special media, and can be expensive and time-consuming. There has been considerable research on in vitro methods for grow-

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

ing hybridomas and these newer methods are less expensive, are faster, and produce antibodies in higher concentration than has been the case in the past. The existence of alternatives to the mouse ascites method raises the question: Is there a scientific need for the mouse ascites method of producing mAb?

The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb.

In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method.

The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.

This report has been reviewed by persons chosen for their diverse perspectives and technical expertise in accordance with procedures approved by the National Research Council's Report Review Committee. The purposes of the independent review are to provide candid and critical comments that will assist the authors and the Research Council in making the published report as sound as possible and to ensure that the report meets institutional standards of objectivity, evidence, and responsiveness to the study charge. The contents of the review comments and the draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following persons for their participation in the review of this report:

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

J. Donald Capra, Oklahoma Medical Research Foundation, Oklahoma City

Philip Carter, North Carolina State University, Raleigh

Joseph Chandler, Maine Biotechnology Services, Inc., Portland

Jon W. Gordon, Mt. Sinai School of Medicine, New York, NY

Coenraad Hendricksen, National Institute of Public Health and the Environment, Bilthoven, The Netherlands

Dave Hill, Oncogene Research Products, Cambridge, MA

Charles A. Janeway, Yale University School of Medicine, New Haven, CT

Neil S. Lipman, Memorial Sloan-Kettering, New York, NY

Uwe Marx, University of Leipzig, Leipzig, Germany

Henry Metzger, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

William E. Paul, National Institute of Allergy and Infectious Diseases, Bethesda, MD

Jon Richmond, Home Office, United Kingdom

Alan Stall, PharMingen, San Diego, CA

Peter Theran, Massachusetts Society for the Prevention of Cruelty to Animals, Boston

Jonathan W. Uhr, University of Texas Southwestern Medical Center, Dallas, TX

Ellen S. Vitetta, University of Texas Southwestern Medical Center, Dallas, TX

The list shows the diversity and background of the reviewers, again attesting to the rigor of the process of producing this report. Although the persons listed have provided many constructive comments and suggestions, responsibility for the final content of this report rests solely with the authoring committee and the National Research Council.

To the committee members, reviewers, and staff, I extend my deepest appreciation. Members of the committee devoted precious weekends, evenings, and work hours and endless energy to meet short deadlines. The reviewers also worked under short deadlines, and their efforts greatly improved the logic, coherence, and comprehensibility of our report.

I am grateful for the guidance and support provided by the Institute for Laboratory Animal Research staff throughout the process. Kathleen Beil provided timely and important communications to the committee in arranging travel and lodging and in report production. Ralph Dell's focus on the topic and his management of the review and publication were of inestimable value. Norman Grossblatt's editing made the report eminently more readable—a feature that will be appreciated by readers.

PETER A. WARD, CHAIR

COMMITTEE ON METHODS OF PRODUCING

MONOCLONAL ANTIBODIES

Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
This page in the original is blank.
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R1
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R2
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R3
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R4
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R5
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R6
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R8
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R9
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R10
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R11
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R13
Suggested Citation:"Front Matter." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page R14
Next: Executive Summary »
Monoclonal Antibody Production Get This Book
×
Buy Paperback | $47.00 Buy Ebook | $37.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb.

In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method.

The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!